These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 20164226

  • 1. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.
    Imhof I, Simmonds P.
    J Virol; 2010 May; 84(9):4597-610. PubMed ID: 20164226
    [Abstract] [Full Text] [Related]

  • 2. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.
    Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
    [Abstract] [Full Text] [Related]

  • 3. Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.
    Gottwein JM, Jensen SB, Serre SB, Ghanem L, Scheel TK, Jensen TB, Krarup H, Uzcategui N, Mikkelsen LS, Bukh J.
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6034-49. PubMed ID: 24060868
    [Abstract] [Full Text] [Related]

  • 4. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.
    Pham LV, Ramirez S, Carlsen THR, Li YP, Gottwein JM, Bukh J.
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348150
    [Abstract] [Full Text] [Related]

  • 5. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).
    Imhof I, Simmonds P.
    Hepatology; 2011 Apr; 53(4):1090-9. PubMed ID: 21480315
    [Abstract] [Full Text] [Related]

  • 6. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
    Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J.
    Gastroenterology; 2011 Sep; 141(3):1067-79. PubMed ID: 21699793
    [Abstract] [Full Text] [Related]

  • 7. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.
    Qi X, Bae A, Liu S, Yang H, Sun SC, Harris J, Delaney W, Miller M, Mo H.
    Antiviral Res; 2009 Feb; 81(2):166-73. PubMed ID: 19063924
    [Abstract] [Full Text] [Related]

  • 8. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX, Moya A, Gonzàlez-Candelas F.
    Antivir Ther; 2008 Feb; 13(4):481-94. PubMed ID: 18672527
    [Abstract] [Full Text] [Related]

  • 9. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
    Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J.
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664
    [Abstract] [Full Text] [Related]

  • 10. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J.
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [Abstract] [Full Text] [Related]

  • 11. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney W, Cheng G.
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [Abstract] [Full Text] [Related]

  • 12. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL, Eyre NS, Black S, Bent SJ, Gaeguta A, Guo Z, Narayana SK, Chase R, Locarnini S, Carr JM, Howe JA, Beard MR.
    Antivir Ther; 2015 Nov; 20(3):271-80. PubMed ID: 25222708
    [Abstract] [Full Text] [Related]

  • 13. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
    He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A.
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1101-10. PubMed ID: 18086851
    [Abstract] [Full Text] [Related]

  • 14. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors.
    Cento V, Mirabelli C, Salpini R, Dimonte S, Artese A, Costa G, Mercurio F, Svicher V, Parrotta L, Bertoli A, Ciotti M, Di Paolo D, Sarrecchia C, Andreoni M, Alcaro S, Angelico M, Perno CF, Ceccherini-Silberstein F.
    PLoS One; 2012 Mar; 7(7):e39652. PubMed ID: 22792183
    [Abstract] [Full Text] [Related]

  • 15. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
    Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslén L, Duberg AS, Lennerstrand J.
    Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
    [Abstract] [Full Text] [Related]

  • 16. Amino Acid Mutations in the NS4A Region of Hepatitis C Virus Contribute to Viral Replication and Infectious Virus Production.
    Murayama A, Sugiyama N, Suzuki R, Moriyama M, Nakamura N, Mochizuki H, Wakita T, Kato T.
    J Virol; 2017 Feb 15; 91(4):. PubMed ID: 27928005
    [Abstract] [Full Text] [Related]

  • 17. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    Pham LV, Jensen SB, Fahnøe U, Pedersen MS, Tang Q, Ghanem L, Ramirez S, Humes D, Serre SBN, Schønning K, Bukh J, Gottwein JM.
    J Hepatol; 2019 Mar 15; 70(3):388-397. PubMed ID: 30395912
    [Abstract] [Full Text] [Related]

  • 18. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
    Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM.
    Antimicrob Agents Chemother; 2016 Jun 15; 60(6):3563-78. PubMed ID: 27021330
    [Abstract] [Full Text] [Related]

  • 19. Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.
    Wose Kinge CN, Espiritu C, Prabdial-Sing N, Sithebe NP, Saeed M, Rice CM.
    Antimicrob Agents Chemother; 2014 Sep 15; 58(9):5386-94. PubMed ID: 24982066
    [Abstract] [Full Text] [Related]

  • 20. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
    Massariol MJ, Zhao S, Marquis M, Thibeault D, White PW.
    Biochem Biophys Res Commun; 2010 Jan 01; 391(1):692-7. PubMed ID: 19944069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.